Supplementary Information for

High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection

Nagai, Moriyama, and Ishii et al.

This file includes:

Supplementary Figures 1-37

Supplementary Table 1



Changes of body temperature following influenza virus infection.

a, **b**, Mice kept at 22 °C were infected intranasally with 1,000 pfu of influenza virus. Body temperatures (**a**; n = 9 mice) and activity of infected mice (**b**; n = 5 mice) were monitored for 7 days. The numbers in parentheses indicate the time of day at which these pictures were taken (**b**). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**a**). **P*<0.05, ****P*<0.001.



Body temperature affects severity of influenza virus infection.

a-d, Mice were kept at 4, 22, or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 4, 22, or 36 °C were infected intranasally with 500 (**a**, **b**) or 2,000 (**c**, **d**) pfu of influenza virus. Body temperatures (**a**, **c**) and mortality (**b**, **d**) were monitored for 14 days (4 °C, n = 8 mice; 22 °C, n = 8 mice; 36 °C, n = 8 mice). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test (**b**, **d**).



Body temperature affects severity of influenza virus infection.

a-d, Mice were kept at 4, 22, or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 4, 22, or 36 °C were infected intratracheally with 1,000 (**a**, **b**) or 10,000 (**c**, **d**) pfu of influenza virus. Body temperatures (**a**, **c**) and mortality (**b**, **d**) were monitored for 14 days (4 °C, n = 5 mice; 22 °C, n = 5 mice; 36 °C, n = 6 mice). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test (**b**, **d**).



Body temperature affects severity of influenza virus pdm09 infection.

a-f, Mice were kept at 4, 22, or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 4, 22, or 36 °C were infected intranasally with 3 $\times 10^4$ pfu (**a**, **b**; 4 °C, *n* = 11 mice; 22 °C, *n* = 11 mice; 36 °C, *n* = 10 mice), 3,000 pfu (**c**, **d**; 4 °C, *n* = 5 mice; 22 °C, *n* = 5 mice; 36 °C, *n* = 6 mice), or 500 pfu (**e**, **f**; 4 °C, *n* = 5 mice; 22 °C, *n* = 5 mice; 36 °C, *n* = 6 mice) of a human isolate of the 2009 pandemic influenza A virus strain A/Narita/1/2009 (pdm09). Body temperatures (**a**, **c**, **e**) and mortality (**b**, **d**, **f**) were monitored for 14 days. Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**a**, **c**, **e**) or log-rank (Mantel-Cox) test (**b**, **d**, **f**). **P*<0.05, ****P*<0.001.



Effects of outside temperature on severity of SARS-CoV-2 infection.

a-d, Syrian hamsters were kept at 4 or 22 °C for 7 d before original SARS-CoV-2 (S-614D) infection and throughout infection. Hamsters kept at 4 or 22 °C were infected intranasally with 1.5×10^6 pfu of an original SARS-CoV-2 (S-614D) strain. Body temperatures (**a**; 4 °C, *n* = 8 hamsters; 22 °C, *n* = 8 hamsters), wight loss (**b**; 4 °C, *n* = 3 hamsters; 22 °C, *n* = 3 hamsters), mortality (**c**; 4 °C, *n* = 8 hamsters; 22 °C, *n* = 15 hamsters; 22 °C, *n* = 15 hamsters) were measured on indicated days after challenge. The dashed line indicates the limit of endpoint. Data are mean ± s.e.m. Data are representative of two independent experiments (**a**, **b**) or are pooled from two (**c**) or three (**d**) independent experiments. Statistical significance was analysed by two-tailed unpaired Student's *t*-test (**a**, **b**, **d**) or log-rank (Mantel-Cox) test (**c**). **P*<0.05, ***P*<0.01, ****P*<0.001, n.s., not significant (**a**; 0 d p.i., *p*=0.002226; 4 d p.i., *p*=0.00184; 8 d p.i., *p*=0.00387; 9 d p.i., *p*=0.0412; 10 d p.i., *p*=0.00261; 11 d p.i., *p*=0.0019; 12 d p.i., *p*=0.00387; 13 d p.i., *p*=0.0152).



Body temperature affects severity of SARS-CoV-2 infection.

a-c, K18-hACE2 mice were kept at 4, 22, or 36 °C for 7 d before original SARS-CoV-2 (S-614D) infection and throughout infection. K18-hACE2 mice kept at 4, 22, or 36 °C were infected intranasally with 5×10^4 pfu of an original SARS-CoV-2 (S-614D) strain. Body temperatures (**a**), weight loss (**b**), and mortality (**c**) were monitored for 14 days (4 °C, n = 5 mice; 22 °C, n = 4 mice; 36 °C, n = 4 mice). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test (**c**).



Effects of outside temperature on severity of SFTSV infection.

a, **b**, One hundred six-weeks-old mice were kept at 4 or 22 °C for 7 d before SFTSV infection and throughout infection. 106-weeks-old mice kept at 4 or 22°C were infected intravenously with 5×10^6 TCID₅₀ of SFTSV. Body temperatures (**a**) and mortality (**b**) were measured on indicated days after challenge (4 °C, *n* = 8 mice; 22 °C, *n* = 8 mice). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-tailed unpaired Student's *t*-test (**a**) or log-rank (Mantel-Cox) test (**b**). * ***P*<0.01, ****P*<0.001 (**a**; 0 d p.i., *p*=0.00011; 2 d p.i., *p*=0.001876; 3 d p.i., *p*=0.000852).



Effects of outside temperature on severity of ZIKV infection.

Mice were kept at 4 or 22 °C for 7 d before ZIKV infection and throughout infection. Mice kept at 4 or 22°C were infected intravenously with 1.5×10^7 pfu of ZIKV. Mortality was monitored for 14 days (4 °C, *n* = 38 mice; 22 °C, *n* = 20 mice). Data are pooled from three independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test.



Effects of outside temperature on severity of EMCV infection.

Mice were kept at 4, 22, or 36 °C for 7 d before EMCV infection and throughout infection. Mice kept at 4, 22, or 36 °C were infected intraperitoneally with 100 pfu of EMCV. Mortality was monitored for 14 days (4 °C, n = 20 mice; 22 °C, n = 20 mice; 36 °C, n = 20 mice). Data are pooled from two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test.



High-heat exposure of aged mice had improved survival after influenza virus

infection.

a, **b**, One hundred seventeen- to 122-weeks-old mice were kept at 22 or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 22 or 36°C were infected intranasally with 1,000 pfu of influenza virus. Body temperatures (**a**) and mortality (**b**) were measured on indicated days after challenge (22 °C, n = 8 mice; 36 °C, n = 8 mice). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-tailed unpaired Student's *t*-test (**a**) or log-rank (Mantel-Cox) test (**b**). ****P*<0.001 (**a**; 0 d p.i., *p*=0.000000248; 4 d p.i., *p*=0.000000304; 7 d p.i., *p*=0.000002735).



Effects of outside temperature on severity of influenza virus infection.

a, **b**, Mice were kept at 22, 28, 34, or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 22, 28, 34, or 36 °C were infected intranasally with 500 pfu of influenza virus. Mortality (**a**) and body temperatures (**b**) were measured on indicated days after challenge (22 °C, n = 10 mice; 28 °C, n = 10 mice; 34 °C, n = 10 mice; 36 °C, n = 10 mice). Data are pooled from two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test (**a**) or two-way analysis of variance (ANOVA) test (**b**). **P*<0.05, ****P*<0.001.



Analysis of gut microbiota composition in high heat-exposed control, LF-fed, or

Abx-treated mice.

Control, LF-fed, or Abx-treated mice were kept at 36 °C for 7 d. **a**, The amounts of DNA extracted from cecal contents were measured by NanoDrop (control, n = 10 mice; LF-fed, n = 5 mice; Abx-treated, n = 10 mice). **b**, **c**, Principal coordinates analysis (PCoA) based on Unweighted (b) or Weighted UniFrac analysis (c) on amplicon sequence variant (ASV). Each symbol represents a single sample of cecal content of high heat-exposed control (n = 10), LF-fed (n = 10), or Abx-treated (n = 10) mice. **d**, **e**, Comparison of order- (**d**) or family- (**e**) level proportional abundance of cecal contents of high heat-exposed control (n = 10), LF-fed (n = 10), LF-fed (n = 10), or Abx-treated (n = 10) mice. **d**, **e** 10) mice. Data are mean ± s.e.m. (**a**) Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**a**). ***P<0.001.



Gut microbiota-derived metabolites protect hamsters from SARS-CoV-2 infection.

a-d, Six-weeks-old hamsters were fed a low fiber (LF)-diet (AIN93G) or antibiotics (Abx) in drinking water for 2 weeks before SARS-CoV-2 infection. Body temperature of LF-fed, Abx-treated, and control uninfected hamsters kept at 22 °C were measured (**a**; control, n = 9 hamsters; LF, n = 9 hamsters; Abx, n =9 hamsters). LF-fed, Abx-treated, and control hamsters kept at 22 °C were infected intranasally with 1.5×10^6 pfu of an original SARS-CoV-2 (S-614D) strain. Mortality (**b**; control, n = 27 hamsters; LF, n = 23 hamsters; Abx, n = 15hamsters) and virus titer in the lung wash (**c**, **d**; control, n = 8 hamsters; LF, n = 8hamsters; Abx, n = 8 hamsters) were measured on indicated days after challenge. Data are mean ± s.e.m. Data are representative of two independent experiments (**a**, **c**, **d**) or are pooled from three (**b**) independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**a**), logrank (Mantel-Cox) test (**b**), or two-tailed unpaired Student's *t*-test (**c**, **d**). *****P*<0.001.



Effects of outside temperature on the cecal metabolome profiles of mice and

hamsters.

a, **b**, PCA plot of the cecal metabolome profiles in mice normalized by Pareto (**a**) and loading scatter plot (**b**). **c**, Box plots indicating cecal amounts of metabolites in mice that had |PC1 coefficient values| > 0.13 in PCA. Significant differences are indicated based on Tukey–Kramer test. **d**, **e**, PCA plot of the cecal metabolome profiles in Syrian hamster normalized by unit variance (**d**) and loading scatter plot (**e**). **f**, Box plots indicating cecal amounts of metabolites in Syrian hamster that had PC1 coefficient values < -0.115 in PCA. Statistical significance was analysed by two-tailed unpaired Student's *t*-test (**c**; DCA,

p=0.002845; Taurine, p=0.000146; Butyrate, p=0.00000009885; **f**; Cholate, p=0.0121; DCA, p=0.130155). The centre line denotes the median value (50th percentile), while the white box contains the 25th to 75th percentiles of dataset. The black whiskers mark the 5th and 95th percentiles (**c**, **f**).



The levels of bile acids in serum.

a-u, Mice were kept at 4, 22, or 36 °C for 7 d. The levels of bile acids in serum were measured (4 °C, n = 9 mice; 22 °C, n = 8 mice; 36 °C, n = 10 mice). Data are mean ± s.e.m. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. **P*<0.05, ***P*<0.01, ****P*<0.001.



The levels of bile acids in Liver.

a-u, Mice were kept at 4, 22, or 36 °C for 7 d. The levels of bile acids in liver were measured (4 °C, n = 9 mice; 22 °C, n = 8 mice; 36 °C, n = 10 mice). Data are mean ± s.e.m. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. **P*<0.05, ***P*<0.01, ****P*<0.001.



The levels of bile acids in serum of high heat-exposed mice.

a-u, LF-fed, Abx-treated, and control mice were kept at 36 °C for 7 d. The levels of bile acids in serum were measured (control, n = 10 mice; LF, n = 10 mice; Abx, n = 10 mice). Data are mean ± s.e.m. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. **P*<0.05, ***P*<0.01, ****P*<0.001.



Bile acids protect mice from influenza virus infection.

a-c, Room temperature-exposed mice given 0.5 mM of UDCA (**a**, **c**) or TDCA were infected intranasally with 1,000 pfu of influenza virus. Mortality (**a**, n = 25 mice for water-fed, n = 30 mice for UDCA-treated; **b**, n = 16 mice for water-fed, n = 17 mice for TDCA-treated) and virus titer in the lung wash (**c**; water, n = 14 mice; UDCA, n = 17 mice) were measured on indicated days after challenge. Data are mean ± s.e.m. Data are pooled from two independent experiments. Statistical significance was analysed by log-rank (Mantel-Cox) test (**a**, **b**), or two-tailed unpaired Student's *t*-test (**c**; p=0.016282). **P*<0.05.



The levels of bile acids in serum of control or CA-treated mice.

a-f, CA (0.5 mM)-treated or control mice were kept at 22°C for 7 d. The levels of bile acids in serum were measured (water, n = 8 mice; CA, n = 8 mice). Data are mean ± s.e.m. Statistical significance was analysed by two-tailed unpaired Student's *t*-test. **P*<0.05 (**d**; *p*=0.017031; **e**; *p*=0.036552; **f**; *p*=0.025267).



Bile acids directly disrupt enveloped viruses.

a-c, Influenza virus (**a**), SARS-CoV-2 (**b**), and EMCV (**c**) were incubated with indicated amounts of DCA at 37 °C for 1 h. Virus titers were measured by standard plaque assay using MDCK (**a**; n = 4), VeroE6/TMPRSS2 (**b**; n = 4), or L929 cells (**c**; n = 6). **d**, **e**, Uninfected-MDCK (**d**; n = 4) or VeroE6/TMPRSS2 (**e**; n = 4) cells were cultured in the presence or absence of indicated amounts of DCA for 24 h. LDH activity was measured for cytotoxicity. Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. **P*<0.05, ****P*<0.001.



Bile acids inhibit influenza virus replication.

a, Effects of bile acids (BAs) on influenza virus replication. Red arrows indicate enhancement. Blue blunt ended bars indicate inhibition. **b-e**, MDCK cells were infected with influenza virus in the presence or absence of 125 μ M of DCA. Cells were collected at 6 h post infection, and intracellularly stained with nucleoprotein (NP)-specific antibody (**b**). Percentages of NP-positive cells are shown (**c**; mock, n = 2; PR8, n = 5; PR8 + DCA, n = 5). Total RNAs were extracted from uninfected or virus-infected cells at 24 h p.i. and influenza virus NP mRNA levels were assessed by quantitative reverse transcription PCR (**d**; n = 6). Cell-free supernatants were collected at 24 and 48 h p.i. and analyzed for virus titer by standard plaque assay using MDCK cells (**e**; n = 6). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**c**, **d**) or two-tailed unpaired Student's *t*-test (**e**). ***P*<0.01, ****P*<0.001 (**e**; 24 h p.i., *p*=0.0000007746; 48 h p.i., *p*=0.00000015).



Effects of TGR5 and FXR agonists on influenza virus replication.

a-c, MDCK cells were infected with influenza virus PR8 (an amantadine-resistant strain) in the presence or absence of indicated amounts of GW 4064, HY-14229, or amantadine. Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies (**a**). Cell-free supernatants were collected at 24 h p.i. and analyzed for virus titer by standard plaque assay using MDCK cells (**b**; DMSO, n = 4; 100 µM, n = 4; 10 µM, n = 8; 1 µM, n = 8). Total RNAs were extracted from uninfected or virus-infected cells at 24 h p.i. and influenza virus NP mRNA levels were assessed by quantitative reverse transcription PCR (**c**; n = 6). Data are mean ± s.e.m. Data are representative of two independent experiments (**a**, **c**) or are pooled from two independent experiments (**b**). Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**b**, **c**). ****P*<0.001, n.s., not significant.



Therapeutic effects of HY-14229 on influenza virus replication.

MDCK cells were infected with influenza virus PR8. After infection, the culture medium was replaced with medium with 1 μ M of HY-14229 at indicated time points. Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies. Data are representative of two independent experiments.



Effects of outside temperature on influenza virus-induced cytokine production.

a-f, Mice were kept at 4, 22, or 36 °C for 7 d before influenza virus infection and throughout infection. Mice kept at 4, 22, or 36 °C were infected intranasally with 1,000 pfu of influenza virus. The lung washes were collected at indicated time points and analyzed for IFN- α (**a**), IFN- β (**b**), IFN- γ (**c**), IFN- λ (**d**), IL-1 β (**e**), and IL-6 (**f**) (n = 3 mice at 0 d p.i., n = 6 mice at 2 d p.i., and n = 7 mice at 3 d p.i.). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. **P*<0.05, ***P*<0.01, ****P*<0.001.



Effects of outside temperature on influenza virus-induced cytokine production.

a-d, LF-fed, Abx-treated, and control mice kept at 36 °C were infected intranasally with 1,000 pfu of influenza virus. The lung washes were collected at 4 d p.i. and analyzed for CXCL1 by ELISA (**a**, n = 36 mice for control, n = 15mice for LF-fed; **b**, n = 30 mice for control, n = 11 mice for Abx-treated). Leucocytes were isolated from the lung at 7 (**c**) or 9 (**d**) d p.i.. The number of Ly6C⁺ Ly6G⁺ neutrophils were analyzed by flow cytometry (**c**, n = 8 mice for control, n = 8 mice for LF-fed; **d**, n = 9 mice for control, n = 10 mice for Abxtreated). Data are mean ± s.e.m. Data are pooled from two independent experiments (**a**, **b**) or are representative of two independent experiments (**c**, **d**). Statistical significance was analysed by two-tailed unpaired Student's *t*-test. **P*<0.05, ***P*<0.01 (**a**; *p*=0.003; **b**; *p*=0.0064; **c**; *p*=0.01131; **d**; *p*=0.01046;).



Treatment of bone marrow-derived macrophages with IL-1β stimulates CXCL1

production.

bone marrow-derived macrophages were stimulated with indicated amounts of recombinant mouse IL-1 β (rIL-1 β). Cell-free supernatants were collected at 24 h post stimulation and analyzed for CXCL1 by ELISA (n = 4). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test. ***P<0.001.



Weight loss and virus titer of SARS-CoV-2-infected hamsters.

a-c, Room temperature-exposed hamsters given 0.5 mM of DCA (**a**, **b**) or CA were infected intranasally with 1.5×10^6 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Weight loss (**a**, **c**; water, n = 16 hamsters; DCA, n = 14 hamsters; CA, n = 16 hamsters) and virus titer in the lung wash (**b**; water, n = 12 hamsters; DCA, n = 12 hamsters) were measured on indicated days after challenge. The dashed line indicates the limit of endpoint. Data are mean ± s.e.m. Data are pooled from two independent experiments. Statistical significance was analysed by two-tailed unpaired Student's *t*-test. **P*<0.05, ***P*<0.01, n.s., not significant (**c**; 4 d p.i., p=0.013699; 10 d p.i., p=0.00111; 14 d p.i., p=0.022192).



Body temperature and the levels of bile acids in serum of cold- and room

temperature-exposed hamsters.

a-d, Hamsters were kept at 4 or 22 °C for 7 d. Body temperature (**a**; 4 °C, n = 8 hamsters; 22 °C, n = 8 hamsters) and the levels of bile acids in serum (**b-d**; 4 °C, n = 10 hamsters; 22 °C, n = 10 hamsters) of naïve hamsters were measured. Data are mean ± s.e.m. Data are representative of two independent experiments (**a**). Statistical significance was analysed by two-tailed unpaired Student's *t*-test. **P*<0.05, ***P*<0.01 (**a**; *p*=0.002226; **b**; *p*=0.032541; **c**; *p*=0.03274; **d**; *p*=0.016035).



Effects of TGR5 and FXR agonists on SARS-CoV-2 replication.

VeroE6/TMPRSS2 cells were infected with original SARS-CoV-2 (S-614D) in the presence or absence of indicated amounts of GW 4064, HY-14229, or amantadine. Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies (n = 2). Data are representative of two independent experiments.



Effects of TGR5 and FXR agonists on SARS-CoV-2 replication in hamsters.

Room temperature-exposed hamsters given 0.1 mM of HY-14229 or GW 4064 were infected intranasally with 1.5×10^6 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Virus titers in the lung washes were measured on indicated days after challenge (water, n = 8 hamsters; HY-14229, n = 8 hamsters; GW 4064, n = 8 hamsters). Data are mean ± s.e.m. Data are pooled from two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test.



Level of serum amyloid A in plasma of COVID-19 patients.

Concentrations of serum amyloid A in plasma of minor (n = 11 patients) versus moderate I/II (n = 35 patients) groups were measured. Each dot represents a unique patient. Data are mean \pm s.e.m. Statistical significance was analysed by a two-tailed Mann-Whitney test. The centre line denotes the median value (50th percentile), while the white box contains the 25th to 75th percentiles of dataset. The black whiskers mark the 5th and 95th percentiles. ****P*<0.001 (*p*=0.0007).



Levels of bile acids in plasma of COVID-19 patients.

a-c, Concentrations of taurine-conjugated CA (TCA) (**a**), taurine-conjugated chenodeoxycholic acid (TCDCA) (**b**), and glycine-conjugated chenodeoxycholic acid (GCDCA) (**c**) in plasma of minor (n = 11 patients) versus moderate I/II (n = 35 patients) groups were measured. Each dot represents a unique patient. Data are mean ± s.e.m. Statistical significance was analysed by a two-tailed Mann-Whitney test. The centre line denotes the median value (50th percentile), while the white box contains the 25th to 75th percentiles of dataset. The black whiskers mark the 5th and 95th percentiles. **P*<0.05, ***P*<0.01 (**a**; *p*=0.0143; **b**; *p*=0.0048; **c**; *p*=0.0012).



The levels of plasma bile acids in COVID-19 patients are negatively correlated

with the level of plasma fibrinogen as a biomarker of COVID-19 disease severity.

a-d, Scatterplots of the levels of plasma bile acids and a fibrinogen. Individual patients are represented as black circles. The solid gray line shows the regression line. R2 and P values were calculated based on the linear regression and two-sided Wald test, respectively. GCA: glycine-conjugated cholic acid, GCDCA: glycine-conjugated chenodeoxycholic acid, TCA: taurine-conjugated chenodeoxycholic acid.



The levels of plasma bile acids in COVID-19 patients are not correlated with the

patients' age.

a-d, Scatterplots of the levels of plasma bile acids and patients' age. Individual patients are represented as black circles. The solid gray line shows the regression line. R2 was calculated based on the linear regression. GCA: glycine-conjugated cholic acid, GCDCA: glycine-conjugated chenodeoxycholic acid, TCA: taurine-conjugated cholic acid, TCDCA: taurine-conjugated cholic acid.



GCA efficiently inhibits SARS-CoV-2 replication.

a, Uninfected-VeroE6/TMPRSS2 cells were cultured in the presence or absence of various amounts (2, 1, 0.5 mM) of DCA, GCA, TCA, GCDCA, or TCDCA for 24 h. LDH activity was measured for cytotoxicity (n = 4). **b**, **c**, VeroE6/TMPRSS2 cells were infected with original SARS-CoV-2 (S-614D) in the presence or absence of indicated amounts of GCA, TCA, GCDCA, or TCDCA. Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies (**b**). Cell-free supernatants were collected at 48 h p.i. and analyzed for virus titer by standard plaque assay using VeroE6/TMPRSS2 cells (**c**; n = 6 tests for DMSO control, n = 3 tests for GCA and TCA). Data are mean ± s.e.m. Data are representative of two independent experiments. Statistical significance was analysed by two-way analysis of variance (ANOVA) test (**a**, **c**). ***P*<0.01, ****P*<0.001.



Virus titer of SARS-CoV-2-infected hamsters.

Room temperature-exposed hamsters given 0.5 mM of GCA were infected intranasally with 1.5×10^6 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Virus titer in the lung wash (water, n = 10 hamsters; DCA, n = 10 hamsters) were measured at 3 d p.i.. Data are mean ± s.e.m. Data are pooled from two independent experiments. Statistical significance was analysed by two-tailed unpaired Student's *t*-test. n.s., not significant.



Gating strategy for identifying neutrophils.

To identify neutrophil population, leucocytes were gated by forward and side scatter. Then, B cells and T cells were excluded based on B220 and CD3 expression, respectively. Ly6C and Ly6G double-positive cells were identified as neutrophils.

| Patient ID | Final symptom | Sex | Age | Ethnicity | Comorbidities | Hospitalization | Discharge | Duration |
|------------|---------------|--------|-----|-----------|------------------------------------|-----------------|------------|----------|
| Tx01001 | Minor illness | Female | 27 | Asian | Mycoplasma pneumonia | 2020/11/7 | 2020/11/14 | 7 |
| Tx01006 | Minor illness | Male | 24 | Asian | Right little finger tendon rupture | 2020/11/11 | 2020/11/21 | 10 |
| Tx01008 | Minor illness | Male | 57 | Asian | HIV | 2020/11/12 | 2020/11/21 | 9 |
| | | | | | Myocardial infarction | | | |
| | | | | | Hemangioma (base of the nose) | | | |
| | | | | | Hypertension | | | |
| | | | | | Dyslipidemia | | | |
| | | | | | Fatty liver | | | |
| Tx01010 | Minor illness | Male | 23 | Asian | Herniated disc | 2020/11/13 | 2020/11/26 | 13 |
| Tx01018 | Minor illness | Male | 21 | Asian | Asthma | 2020/11/22 | 2020/12/1 | 9 |
| Tx01020 | Minor illness | Female | 29 | Asian | N/A | 2020/11/20 | 2020/11/26 | 6 |
| Tx01035 | Minor illness | Male | 55 | Asian | Diabetes | 2020/11/27 | 2020/12/24 | 27 |
| | | | | | Liver cancer | | | |
| | | | | | Bacteremia | | | |
| | | | | | Colon polyps | | | |
| | | | | | Portal vein thrombosis | | | |
| | | | | | Peritonitis | | | |
| | | | | | Esophageal varices | | | |
| | | | | | Thyroid mass | | | |
| Tx01055 | Minor illness | Female | 79 | Asian | Angina pectoris | 2021/2/26 | 2021/3/9 | 11 |
| | | | | | Dyslipidemia | | | |

Supplementary Table 1. Demographic and background information for 46 patients.

| | | | | | Osteoporosis | | | |
|---------|---------------|--------|-----|-------|------------------------------------|------------|---------------------------------------|----|
| | | | | | Uterine fibroid | | | |
| | | | | | Fallopian tube obstruction disease | | | |
| Tx01058 | Minor illness | Female | 26 | Asian | Pulmonary embolism | 2021/3/11 | 2021/3/22 | 11 |
| | | | | | Insomnia | | | |
| Tx01071 | Minor illness | Male | 42 | Asian | Restless legs syndrome | 2021/3/5 | 2021/3/15 | 10 |
| | | | | | Hypertension | | | |
| | | | | | Sleep apnea syndrome | | | |
| Tx01079 | Minor illness | Male | 27 | Asian | X-linked agammaglobulinemia | 2021/2/14 | 2021/2/23 | 9 |
| Tx01002 | Moderate I | Male | 53 | Asian | Hepatitis B | 2020/11/8 | 2020/11/20 | 12 |
| Tx01011 | Moderate I | Male | 27 | Asian | Familial Mediterranean fever | 2020/11/14 | 2020/11/23 | 9 |
| | | | | | Type 2 diabetes | | | |
| | | | | | Hypertension | | | |
| | | | | | Dyslipidemia | | | |
| | | | | | Obesity Type 3 | | | |
| | | | | | Sleep apnea syndrome | | | |
| Tx01012 | Moderate I | Male | 49 | Asian | Vagal reflex | 2020/11/16 | 2020/11/22 | 6 |
| | | | | | Dyslipidemia | | | |
| | | | | | Hypertension | | | |
| | | | | | Gout | | | |
| | | | | | Hyperuricemia | | | |
| Tx01015 | Moderate I | Female | 71 | Asian | Type 2 diabetes | 2020/11/18 | 2020/11/27 | 9 |
| | | | , = | | Lumbar spondylolisthesis | | · · · · · · · · · · · · · · · · · · · | - |

| | | | | | Herpes zoster | | | |
|---------|------------|--------|----|-------|-------------------------------------|------------|------------|----|
| | | | | | Dyslipidemia | | | |
| Tx01021 | Moderate I | Male | 50 | Asian | Gastric ulcer | 2020/11/21 | 2020/11/28 | 7 |
| Tx01023 | Moderate I | Male | 71 | Asian | Diabetes mellitus | 2020/11/23 | 2020/12/2 | 9 |
| | | | | | Hypertension | | | |
| | | | | | Cholesteatoma | | | |
| Tx01025 | Moderate I | Female | 77 | Asian | Appendicitis | 2020/11/25 | 2020/12/11 | 16 |
| | | | | | Kidney stones | | | |
| | | | | | Progressive supranuclear palsy | | | |
| Tx01027 | Moderate I | Male | 44 | Asian | Asthma | 2020/11/25 | 2020/12/8 | 13 |
| Tx01032 | Moderate I | Male | 23 | Asian | Influenza-associated encephalopathy | 2020/11/27 | 2020/12/2 | 5 |
| Tx01034 | Moderate I | Female | 66 | Asian | Hypothyroidism | 2020/11/29 | 2020/12/2 | 3 |
| | | | | | Hypertension | | | |
| Tx01051 | Moderate I | Female | 79 | Asian | Uterine fibroid | 2020/12/24 | 2021/1/2 | 9 |
| | | | | | Hypertension | | | |
| | | | | | Diabetes mellitus | | | |
| Tx01053 | Moderate I | Male | 22 | Asian | X-linked agammaglobulinemia | 2021/2/14 | 2021/2/23 | 9 |
| | | | | | Pneumonia | | | |
| | | | | | Appendicitis | | | |
| Tx01054 | Moderate I | Male | 38 | Asian | N/A | 2021/2/26 | 2021/3/7 | 9 |
| Tx01057 | Moderate I | Female | 68 | Asian | Asthma | 2021/2/2 | 2021/2/17 | 15 |
| | | | | | Colon cancer | | | |
| | | | | | Cataract | | | |

| | | | | | Glaucoma | | | |
|---------|------------|--------|----|-------|-------------------------|------------|------------|----|
| Tx01059 | Moderate I | Male | 40 | Asian | N/A | 2020/12/1 | 2020/12/5 | 4 |
| Tx01061 | Moderate I | Male | 35 | Asian | N/A | 2020/12/26 | 2021/1/8 | 13 |
| Tx01064 | Moderate I | Male | 48 | Asian | Alcoholic liver disease | 2021/2/4 | 2021/2/24 | 20 |
| | | | | | Asthma | | | |
| | | | | | Depression | | | |
| | | | | | Psoriasis vulgaris | | | |
| | | | | | Gout | | | |
| Tx01066 | Moderate I | Female | 63 | Asian | Parkinson's disease | 2020/12/11 | 2020/12/26 | 15 |
| Tx01070 | Moderate I | Male | 61 | Asian | Myocardial infarction | 2020/12/26 | 2021/1/3 | 8 |
| | | | | | Diabetes mellitus | | | |
| | | | | | Hypertension | | | |
| | | | | | Dyslipidemia | | | |
| Tx01074 | Moderate I | Male | 66 | Asian | Diabetes mellitus | 2020/12/25 | 2021/1/8 | 14 |
| | | | | | Hypertension | | | |
| | | | | | Dyslipidemia | | | |
| | | | | | Hyperuricemia | | | |
| | | | | | Gout | | | |
| Tx01076 | Moderate I | Female | 81 | Asian | Small cell lung cancer | 2021/1/30 | 2021/2/16 | 17 |
| | | | | | Diabetes mellitus | | | |
| | | | | | Hypertension | | | |
| | | | | | Arrhythmia | | | |
| | | | | | Neurosis | | | |

| Tx01077 | Moderate I | Male | 48 | Asian | Hypertension | 2021/2/27 | 2021/3/9 | 10 |
|---------|-------------|--------|----|-------|-------------------------|------------|------------|----|
| Tx01080 | Moderate I | Female | 89 | Asian | Chronic renal failure | 2021/2/4 | 2021/2/15 | 11 |
| | | | | | Asthma | | | |
| | | | | | Tuberculosis | | | |
| Tx01082 | Moderate I | Male | 70 | Asian | Herniated disc | 2020/12/4 | 2020/12/15 | 11 |
| | | | | | Urinary retention | | | |
| | | | | | Prostatic hypertrophy | | | |
| Tx01003 | Moderate II | Male | 59 | Asian | Dyslipidemia | 2020/11/8 | 2020/11/21 | 13 |
| | | | | | Sleep apnea syndrome | | | |
| | | | | | Hyperuricemia | | | |
| | | | | | Hemorrhoid | | | |
| | | | | | Fatty liver | | | |
| Tx01013 | Moderate II | Female | 84 | Asian | Hypertension | 2020/11/16 | 2020/11/27 | 11 |
| Tx01052 | Moderate II | Male | 82 | Asian | Myocardial infarction | 2021/1/18 | 2021/2/2 | 15 |
| | | | | | Dyslipidemia | | | |
| | | | | | Appendicitis | | | |
| | | | | | Hypertension | | | |
| | | | | | Right thigh abscess | | | |
| | | | | | Alcoholic liver disease | | | |
| | | | | | Diabetes mellitus | | | |
| Tx01062 | Moderate II | Male | 81 | Asian | Prostate cancer | 2021/1/26 | 2021/2/20 | 25 |
| | | | | | Diverticular bleeding | | | |
| | | | | | Duodenal ulcer | | | |

| | | | | | Cataract | | | |
|---------|-------------|--------|----|-------|----------------------------------|------------|------------|----|
| Tx01063 | Moderate II | Female | 76 | Asian | T12/L1 Herniated disc | 2020/12/6 | 2020/12/29 | 23 |
| | | | | | Hypertension | | | |
| | | | | | Asymptomatic cerebral infarction | | | |
| | | | | | Old T12 compression fracture | | | |
| Tx01065 | Moderate II | Male | 64 | Asian | N/A | 2020/11/30 | 2020/12/8 | 8 |
| Tx01067 | Moderate II | Male | 81 | Asian | Dementia | 2021/1/19 | 2021/1/31 | 12 |
| | | | | | Stroke sequelae | | | |
| | | | | | Hyperuricemia | | | |
| Tx01069 | Moderate II | Female | 67 | Asian | Dyslipidemia | 2021/1/17 | 2021/2/14 | 28 |
| | | | | | Bilateral hip osteoarthritis | | | |
| Tx01073 | Moderate II | Female | 86 | Asian | Hypertension | 2020/12/6 | 2020/12/15 | 9 |
| | | | | | Dyslipidemia | | | |
| Tx01081 | Moderate II | Male | 59 | Asian | Angina pectoris | 2021/2/17 | 2021/3/3 | 14 |
| | | | | | Lumbar hernia | | | |
| | | | | | Mediastinal lymphadenopathy | | | |
| | | | | | Autonomic dysregulation | | | |
| | | | | | Gastric ulcer | | | |
| | | | | | High blood pressure | | | |
| Tx01083 | Moderate II | Male | 67 | Asian | Hypertension | 2021/5/14 | 2021/5/27 | 13 |
| | | | | | Hyperuricemia | | | |
| | | | | | Prostate cancer | | | |

Uncropped scans of blots:



Supplementary Fig. 22a



Supplementary Fig. 23



Supplementary Fig. 29



Supplementary Fig. 35b